In 2023, CytoAurora established HUA TEC International to spearhead the development of the Nano CAST™ Cancer Solution. HUA TEC focuses not only on cancer screening but also on immune cell analysis, marking a new chapter in rare cell detection and non-invasive prenatal testing, and offering the potential to benefit a large number of people worldwide.
World-leading core technology: HUA TEC combines semiconductor, artificial intelligence, and biomedicine to develop patented technology aimed at advancing single-cell research and applications. They have created fully automated systems merging semiconductor and single-cell tech into biomedical innovations.
Their blood detection chip leverages Taiwan's semiconductor strengths, AI software, and molecular pathology to create globally leading cancer detection devices, supported by Taiwan's National Research Institute and clinical programs.
HUA TEC offers high-quality instruments, reagents, chips, and technical support. Their team includes experts in life sciences, biochemistry, and bioinformatics, focusing on accurate cell and molecular pathology analysis. They develop bioassays using CTC enumeration and biomarker profiling for insights into tumor behavior and treatment response.
HUA TEC specializes in semiconductor biochips, enabling high-throughput, high-precision biomolecular analysis. Their cross-disciplinary team includes experts in semiconductors, physics, chemistry, biotech, and mechanical engineering. They provide chips for biological experiments with and without semiconductor substrates.
Using image recognition and machine learning, HUA TEC analyzes cellular images with speed and precision. Their team combines programming, data analysis, and algorithm optimization to ensure cutting-edge diagnostic software aligned with ongoing biomedical research.
They have developed automated systems for cell enrichment, staining, and single-cell handling to reduce manual workload and human error.
